Language
English
Publication Date
6-13-2024
Journal
Clinical Microbiology Reviews
DOI
10.1128/cmr.00099-23
PMID
38546225
PMCID
PMC11237761
PubMedCentral® Posted Date
3-28-2024
PubMedCentral® Full Text Version
Post-print
Abstract
As Chagas disease remains prevalent in the Americas, it is important that healthcare professionals and researchers are aware of the screening, diagnosis, monitoring, and treatment recommendations for the populations of patients they care for and study. Management of Trypanosoma cruzi infection in immunocompromised hosts is challenging, particularly because, regardless of antitrypanosomal treatment status, immunocompromised patients with Chagas disease are at risk for T. cruzi reactivation, which can be lethal. Evidence-based practices to prevent and manage T. cruzi reactivation vary depending on the type of immunocompromise. Here, we review available data describing Chagas disease epidemiology, testing, and management practices for various populations of immunocompromised individuals, including people with HIV and patients undergoing solid organ and hematopoietic stem cell transplantation.
Keywords
Humans, Immunocompromised Host, Chagas Disease, Trypanosoma cruzi, Chagas disease, Trypanosoma cruzi, immunocompromised hosts, human immunodeficiency virus, bone marrow transplantation, organ transplantation
Published Open-Access
yes
Recommended Citation
Clark, Eva H; Messenger, Louisa A; Whitman, Jeffrey D; et al., "Chagas Disease in Immunocompromised Patients" (2024). Faculty and Staff Publications. 4677.
https://digitalcommons.library.tmc.edu/baylor_docs/4677